Brachytherapy in Carcinoma of Lung & Esophagus



Dr. D.N. Sharma Associate Professor Department of Radiation Oncology All India Institute of Medical Sciences

Brachytherapy in non small cell lung cancer

- Limited practice
- Used in selective patients
- Highly conformal treatment
- Complicated technique
- Skilled procedure

Brachytherapy in NSCLC

Brachytherapy alone
 As definitive treatment alone
 As palliative treatment

Combined with EBRT (dose escalation/boost)

• Combined with surgery

Types of Brachytherapy for NSCLC

Intraluminal/ endobronchial

Interstitial

Trans-cutaneous

Intraoperative

Perioperative

ILRT

Curative Intent Along With ERT
Palliative Intent
Emergency Management

SVC
* Bleeding









Risk of Hemoptysis with ILRT: Literature

Author	n	HDR-Dose (Gy)	Ref.Point	Previous EBRT ?	Massive hemoptysis (%)
Seagren	20	1*10 Gy	@ 10 mm	Yes	28 %
Mehta 1	31	4*4 Gy	@ 10 mm	Yes	3 %
Roach 1	17	30 Gy LDR	@ 5 mm	Yes	0 %
Bedwine	32	3*6 Gy	@ 10 mm	Yes	32 %
Aygun 1	60	4 * 5 Gy	@ 10 mm	Yes	15 %
Sutedja	31	3*10 Gy	@ 10 mm	Yes	32 %
Gollins 1	402	1 * 15-20Gy	@ 10 mm	No (324)	8 %
Hennequ	149	4-6 * 7Gy	@ 10 mm	Yes	7.4 %
Speiser a (24)	295	3 * 10 Gy 3 * 7.5 Gy	@ 10 mm @ 10 mm	Yes Yes	6.3 % 8.6 %

Interstitial Brachytherapy

- Complicated procedure, but very precise method of radiation delivery
- Done under CT Guidance
- Suitable for peripheral lesions
- Very limited experience in the literature









Intra-operative RT

- Relatively new technique of RT
- Not yet established
- Fraction Size 10-20Gy followed by EBRT

Intraoperative Radiotherapy



Permanent brachytherapy implant





Brachytherapy for Carcinoma of Esophagus

Brachytherapy alone For palliative treatment For definitive treatment
Brachytherapy + EBRT : For boost

Performed in the form of Intraluminal RT (ILRT)

Intraluminal Radiotherapy (ILRT)

Rationale

- Dose fall off is very sharp, hence minimal doses to surrounding organs
- Higher dose can be given in shorter time

Procedure

 Endoscopic assessment → Insertion of esophageal applicator (Rowland's applicator) → Source loading on Remote afterloading unit

Dose 12-15 Gy at 0.5-1.0 cm (LDR)









Contraindications for ILRT

- Severe stenosis where applicator can't be negotiated
- T.O. fistula
- Primary tumor > 10 cm long
- Gross mediastinal L. adenopathy
- Pts with skip lesions
- Extension to cardia

Pall ILRT: AIIMS Data*

- 34 cases treated with ILRT (LDR)
- With or without previous EBRT
- Dose 12-15 Gy (LDR)
- Swallowing capacity improved in 60% pts
- Incidence of post RT stenosis : 11%

* TROP GASTROENTEROL 1996

Literature

- Dinshaw et al. ILRT+5FU...JSO 1991
 After 50 Gy EBRT, 50 pts randomised to ILRT alone vs ILRT + 5FU, 2 yr surv : 15% vs 22%.
- Sur et al. Role of HDR ILRT. IJROBP 1992 After 35 Gy EBRT, 50 pts randomised to
 - further 20 Gy EBRT vs.
 - HDR ILRT 12 GY (2x6Gy weekly F)

1-yr survival : 44% vs. 78% (p value<0.001).

Vivekanandam et al. EBRT+ILBT. Am J Clin Oncol
 59 pts treated by 36 Gy EBRT+30 Gy ILBT (LDR)
 1-yr surv= 24%, Mean surv=9.6 mo

American Brachytherapy Society Guidelines

- EBRT : 45-50 Gy by Conventional Fractionation
- ILRT after 2-3 wks of EBRT completion
- HDR : 5 Gy once a week X 2
- LDR : 20 Gy single session, 0.4-1.0 Gy/hr
- Dose prescription at 1.0 cm from mid-source or middwell position

Conclusion (Brachy in Lung Cancer)

- Limited role but highly conformal
- Practiced in few centers
- Endobronchial brachytherapy is the main form
- Intra-operative and percutaneous Brachy requires special skill and expertise
- Limited studies in literature

Conclusion (Brachy in Esophageal Cancer)

- Technically it is relatively easier
- Mainly used for palliation: effective
- For escalating the dose after EBRT
- Risk of stenosis stricture after ILRT : 20-30%